Announcements Trials
Browse Landscape

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Lung Neoplasms 2Breast Neoplasms 2Thymus Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumor 1Mesothelioma 1Melanoma 1Head and Neck Neoplasms 1Carcinoma, Squamous Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Adenocarcinoma 1

Interventions

Injections 6pembrolizumab 5senaparib 4toripalimab 3tislelizumab 3Bevacizumab 3sintilimab 2Technetium 2Specimen Handling 2Nivolumab 2Ipilimumab 2Fluorodeoxyglucose F18 2Carboplatin 2Blood Specimen Collection 2zimberelimab 1tumor-cells apoptosis factor, human 1tazemetostat 1spartalizumab 1sacituzumab govitecan 1rucaparib 1osimertinib 1olaparib 1etoposide phosphate 1enzalutamide 1envafolimab 1cemiplimab 1cedazuridine 1atezolizumab 1WW Domain-Containing Oxidoreductase 1Ultrasonography, Doppler 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Solid Tumor × Histocompatibility Testing × 1 year × Clear all
NCT06895681 2026-05-04

UCSF Biobank for Hereditary Cancers and Tumor-Associated Mutations

University of California, San Francisco

Not yet recruiting
50,000 enrolled
Other solid neoplasm

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡